Category Archives: Cancer and neoplasms

Specialty

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Trabedersen overview Trabedersen (OT-101) is under development for the treatment of […]

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. SOR-007 overview Paclitaxel is under development for the treatment of pancreatic […]

There is no national screening program for breast cancer for women under 40. This is because the risk of breast cancer is higher in women over 50. However, breast cancers in young women tend to be larger, more advanced at diagnosis and more aggressive. Because these cancers aren’t caught early, and are more difficult to […]

Specialty

Abstract Big data serves as the cornerstone for constructing real-world deep learning systems across various domains. In medicine and healthcare, a single clinical site lacks sufficient data, thus necessitating the involvement of multiple sites. Unfortunately, concerns regarding data security and privacy hinder the sharing and reuse of data across sites. Existing approaches to multi-site clinical […]

Abstract Despite the dedicated research of artificial intelligence (AI) for pathological images, the construction of AI applicable to histopathological tissue subtypes, is limited by insufficient dataset collection owing to disease infrequency. Here, we present a solution involving the addition of supplemental tissue array (TA) images that are adjusted to the tonality of the main data […]

Abstract Cancer stem cells (CSCs) are believed to be crucial in the initiation, progression, and recurrence of cancer. CSCs are also known to be more resistant to cancer treatments. However, the interaction between CSCs and the immune microenvironment is complex and not fully understood. In current study we used single cell RNA sequence (scRNA-Seq, public […]

Abstract In an observational study conducted from 2016 to 2021, we assessed the utility of radiomics in differentiating between benign and malignant lung nodules detected on computed tomography (CT) scans. Patients in whom a final diagnosis regarding the lung nodules was available according to histopathology and/or 2017 Fleischner Society guidelines were included. The radiomics workflow […]

Joseph M. Scandura, MD, PhD Multiple studies are evaluating pelabresib (CPI-0610) for the treatment of patients with myeloproliferative neoplasms (MPNs). With more data on the agent expected to be released from trials in this space toward the end of the year, Joseph M. Scandura, MD, PhD, reflected on its potential role for patients with myelofibrosis […]